Advertisement
Advertisement

GUTS

GUTS logo

Fractyl Health, Inc. Common Stock

0.50
USD
Sponsored
+0.07
+15.24%
Mar 25, 16:00 UTC -4
Closed
exchange

Pre-Market

0.47

-0.03
-6.80%

GUTS Earnings Reports

Positive Surprise Ratio

GUTS beat 4 of 8 last estimates.

50%

Next Report

Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.15
Implied change from Q4 25 (Revenue/ EPS)
--
/
-200.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/
-69.39%

Fractyl Health, Inc. Common Stock earnings per share and revenue

On Mar 24, 2026, GUTS reported earnings of 0.15 USD per share (EPS) for Q4 25, beating the estimate of -0.18 USD, resulting in a 181.70% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.23% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -0.15 USD, with revenue projected to reach -- USD, implying an decrease of -200.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
logo
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
logo
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
logo
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
logo
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
logo
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-
Surprise
-
logo
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
logo
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
logo
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
FAQ
For Q4 2025, Fractyl Health, Inc. Common Stock reported EPS of $0.15, beating estimates by 181.7%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.23%, changed from $0.51 before the earnings release to $0.50 the day after.
The next earning report is scheduled for May 12, 2026.
Based on 4 analysts, Fractyl Health, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement